Proactive Investors - Run By Investors For Investors

Alliance Pharma launches the UK's only prescription drug for nausea and vomiting during pregnancy

Sold under the brand name Xonvea, the treatment was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years
pregnant woman
Around 40% suffer nausea and vomiting during pregnancy

Alliance Pharma plc (LON:APH) has launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.

Sold under the brand name Xonvea, Diclectin was licensed from Duchesnay of Canada in 2015 and has been prescribed to 33mln women over 40 years. Marketing approval from the Medicines and Healthcare products Regulatory Agency took longer than anticipated but was granted over the summer.

Nausea and vomiting are the most common medical condition during pregnancy and affects around 40% of women.

Milestone

Professor Catherine Nelson-Piercy, a consultant obstetric physician, welcomed the launch of Xonvea, saying: “This delayed release formulation of doxylamine and pyridoxine has been used in millions of pregnant women worldwide.” 

“Primary and secondary care doctors caring for pregnant women in the UK are now able to prescribe Xonvea, affording women in the UK a licensed option when it comes to managing this often debilitating condition.”

Alliance chief executive Peter Butterfield called the drug launch a “significant milestone” for pregnant women and the company.

“There is no other licensed treatment for nausea and vomiting of pregnancy in the UK so this is excellent news for patients and clinicians as it fulfils a significant unmet medical need," he added.

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use